AMC-087: Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus (H-33163)
AMC-087: Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection
This phase I trial studies the side effects and best dose of cabozantinib-s-malate in treating patients with advanced solid tumors and human immunodeficiency virus. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
The primary objective is to determine the safety and tolerability of cabozantinib (XL184) (cabozantinib-s-malate) as a single agent in solid tumor patients with human immunodeficiency virus (HIV) infection and to determine the maximal tolerated dose (MTD) in this patient population.
Patients receive cabozantinib-s-malate orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 30 days.
Patients must have known HIV infection and histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
For more information: http://clinicaltrials.gov/ct2/show/NCT01822522